TSO3 announces the Results of the Votes from its Annual and Special Meeting of the Shareholders

QUÉBEC CITY, May 5, 2016 /CNW Telbec/ - TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated March 22, 2016, were elected as directors of TSO3 Inc. In addition, all other proposals submitted by management were approved.

­Election of Directors

The shareholders were asked to provide their decision via a vote by proxy as part of TSO3 Annual General Meeting of Shareholders, held on May 4, 2016 in Québec. The detailed results of the vote are set out below.

 

 

Name

Votes for

% for

Votes
against

%
against

Withheld/

Abstain

%
withheld

Germain Carrière

35,429,726

95.17

0

0

1,799,908

4.83

Pierre Désy

36,463,106

97.94

0

0

766,528

2.06

Jean Lamarre

35,388,316

95.05

0

0

1,841,318

4.95

Claude Michaud

35,790,756

96.14

0

0

1,438,878

3.86

Jean-Pierre Robert

36,840,666

98.96

0

0

388,968

1.04

Richard M. Rumble

37,189,728

99.89

0

0

39,906

0.11

Steve West

37,182,448

99.87

0

0

47,186

0.13








Other Proposals














Appointment of Independent Auditors

41,759,965

99.95

0

0

21,035

0.05

Adoption of the 2016 Stock Incentive Plan

24,293,413

65.25

12,936,221

34.75

0

0.00

Increase the number of the Stock Option Plan

29,928,651

80.39

7,300,983

19.61

0

0.00

Amendments to articles

36,266,128

97.41

963,506

2.59

0

0.00

­

Final voting results on all matters voted at the Annual Meeting of Shareholders held on May 4, 2016, will be filed on SEDAR (www.sedar.com) under the name TSO3.

About TSO3

Founded in 1998, TSO3 is committed to improving the standard of healthcare sterile reprocessing by providing breakthrough sterilization systems, related consumable supplies and accessories for heat-sensitive medical devices. TSO3 designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the company's web site at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO3's sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

 

SOURCE TSO3 Inc.

For further information: Company Contacts: TSO3 Inc., R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, Email: info@tso3.com; TSO3 Inc., Glen Kayll, CFO, Tel: 418 651-0003, Email: info@tso3.com; Investor Relations: Liolios Group, Inc., Ron Both, Tel: 949 574-3860, TOS@liolios.com; Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, bmire@renmarkfinancial.com

RELATED LINKS
http://www.tso3.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890